Prokarium raises $10 million for clinical development of thermostable vaccines

UK-based synthetic biology company, Prokarium, has completed an investment round, raising $10 million for the clinical development of vaccines against chlamydia, C.difficile and enteric fever, plus an expansion for the immune-oncology R&D team Read more

26 Feb 2018 13:11 News